Figure 3. Suppressive effect of PAC on proliferation and lipogenesis in IGF-1-stimulated SEB-1 sebocytes. (a) Cell cycle progression in SEB-1 sebocytes was analyzed by flow cytometry. Marker 1 (M1) represents apoptotic cells; (b) SEB-1 sebocytes were treated with 20 nM of IGF-1 with 1 ug/ml PAC or 1 uM EGCG treatments for 24 h. Nile red staining was performed to detect lipid (Sebum) production of SEB-1 sebocytes.
3.6. Clinical Effect of PAC-Containg Test Product on Acne Prone Skin
To investigate the efficacy of PAC-containing test product versus a control product, the test and control product were applied twice a day for a 4-weeks on 20 volunteers. The skin oil content (μg/ml), number of skin sebum, numbers of non-inflammatory and inflammatory acne lesion was measured before treatment, at 2 weeks and 4 weeks following 4 consecutive weeks treatment of test product. The results showed a significant decrease in skin oil content of 48.9%
(a) (b) (c) (d) (e)
Figure 4. Effect of Figure 4. Effects of application of PAC-containing test product on acne lesions in a 4-weeks human clinical study. Skin oil content (a); Number of skin sebum (b); Number of whiteheads (c); Number of blackheads (d); and photographs of the faces of control product group (control group) and PAC-containing test product group (PAC group) (e). *P < 0.05 compared with before treatment.
after 4 weeks and sebum secretion rate of 17.6% after 2 weeks (Figure 4(a), Figure 4(b)). Compared to before treatment, the number of whiteheads and blackheads were significantly reduced at PAC-containg test product group at 2 weeks and 4 weeks (Figure 4(c), Figure 4(d)). In addition, compared to the control product group at 4 weeks, PAC-containg test product group significant reduction of 27.2% and 11.3% in the mean number of whiteheads and blackheads. Papules and pustules were showed a tendency to decrease at 4 weeks in PAC-containing test product group compared to the control product group (Table 3). These results indicate that the PAC complex exerts an acne-mitigating effect.
3.7. Human Skin Primary Irritation Test of PAC
A skin primary irritation test in humans was conducted to evaluate the irritation potential of PAC on human skin. A human patch test is a general method that is used to determine the human skin safety of a substance for clinical applications. The patch test was usually removed after 48 hours, and readings were recorded 30 minutes after removing the strips (day 2) and after 24 (day 3) or 48 (day 4) hours, as modified by Frosch & Kligman  . 31 healthy volunteers aged 20 to 50 years (average 41.6 ± 6.5 yrs) were recruited for this study. During this study, none of the 31 subjects experienced a reaction based on the 48- and 72-h readings (Table 4) and PAC did not induce any skin reaction. Therefore, these data demonstrate that the PAC is within the scope of the slight-irritation and is safe to apply to human skin.
Acne is characterized by multifactorial conditions, including hormonal imbalance, abnormal ductal keratinization, bacterial overgrowth, inflammation, and excessive sebum production. Despite the existence of many studies on the pathophysiological mechanisms of acne, the development of effective ingredients for treatment has been limited because such substances have shown a single effect among multiple physiological factors of acne, not on multiple aspects   . Recently, there has been an increasing focus on developing therapeutic agents that target multiple pathogenesis of acne, with no side effects. Pretsch et al. reported that Talaromyces wortmannii extracts have an anti-microbial activity against acne-inducing bacteria including P. acnes and anti-inflammatory properties by inhibiting P. acnes-mediated activation of NF-kB and activator protein-1 (AP-1) activation, as well as IL-8 release  . Results from in vitro, ex vivo, and clinical studies on BGM complex composed of bakuchiol, Ginkgo biloba extract, mannitol for acne therapy showed antibacterial activity against
Table 3. Statistical analysis of whiteheads, blackheads, papule and pustule by lesion counting.
*Significantly different at P < 0.05 compared with control group.
Table 4. Human skin primary irritation test.
P. acne, antioxidation activity of squalene, anti-inflammatory activity and regulation of sebum composition  .
In the current study, we first report on the antibacterial activity against P. acnes of Pinus thunbergii needle extract, Artemisia annua L. extract, and Citrus junos Tanaka fruit juice and anti-inflammatory activity of Pinus thunbergii needles extract and Artemisia annua L. extract.
We also assessed antibacterial properties against P. acnes and S. epidermidis, anti-inflammatory potential of a new combined plant extract (PAC), consisting of Pinus thunbergii needle extract, Artemisia annua L. extract, and Citrus junos Tanaka fruit juice. PAC showed the lowest MIC value of 2.25 mg/ml and 0.75 mg/ml against P. acnes and S. epidermidis and was more effective than LP and AA on inhibition of P. acnes- and LPS-stimulated inflammation. In addition, we evaluated sebosupressive and clinical effect on acne prone skin of PAC whether PAC can regulate multiple pathogenic factor of acne. The results indicated that PAC had suppressive effect on differentiation and lipogenesis in IGF-1-stimulated SEB-1 cells. In clinical study, compared to the control product group at 4 weeks, skin oil content, skin sebum number, and the numbers of whiteheads and blackheads in PAC-containg test product group were significantly decreased. Furthermore, a patch test was performed to confirm the safety of PAC, and it did not show any adverse reactions on human skin.
Based on these results, this study suggests that PAC may be introduced as a potential therapeutic agent for acne vulgaris.
In summary, our results reveal that PAC is effective in suppressing multifactorial pathological conditions of acne, including antimicrobial activities against and S. epidermidis, anti-inflammatory activities, sebo-suppressive effects, and reduction of skin oil content, sebum number, and the numbers of acne lesions. Therefore, this study demonstrated that the PAC can improve acne treatment and can be provided as an effective new agent for acne therapy.
This research was supported by the Ministry of Trade, Industry & Energy (MOTIE), Korea Institute for Advancement of Technology (KIAT) through the Encouragement Program for The Industries of Economic Cooperation Region.
Conflicts of Interest
The authors declare no conflicts of interest.
|||Whiting, D.A. (1979) Acne. The Western Journal of Medicine, 131, 551-557.|
Zouboulis, C.C., Seltmann, H., Hiroi, N., Chen W., Young, M., Oeff, M., Scherbaum, W.A., Orfanos, C.E., McCann, S.M. and Bornstein, S.R. (2002) Corticotropin-Releasing Hormone: An Autocrine Hormone That Promotes Lipogenesis in Human Sebocytes. Proceedings of the National Academy of Sciences of the United States of America, 99, 7148-7153.
Haider, A. and Shaw, J.C. (2004) Treatment of Acne Vulgaris. The Journal of the American Medical Association, 292, 726-735.
Toyoda, M. and Morohashi, M. (2001) Pathogenesis of Acne. Medical Electron Microscopy, 34, 29-40.
|||Harper, J.C. and Thiboutot, D.M. (2003) Pathogenesis of Acne: Recent Research Advances. Advances in Dermatology, 19, 1-10.|
Thiboutot, D. (2004) Regulation of Human Sebaceous Glands. Journal of Investigative Dermatology, 123, 1-12.
Kim, J., Ochoa, M.T., Krutzik, S.R., Takeuchi, O., Uematsu, S., Legaspi, A.J., Brightbill, H.D., Holland, D., Cunliffe, W.J., Akira, S., Sieling, P.A., Godowski, P.J. and Modlin, R.L. (2002) Activation of Toll-Like Receptor 2 in Acne Triggers Inflammatory Cytokine Responses. Journal of Immunology, 169, 1535-1541.
Jugeau, S., Tenaud, I., Knol, A.C., Jarrousse, V., Quereux, G., Khammari, A. and Dreno, B. (2005) Induction of Toll-Like Receptors by Propionibacterium acnes. British Journal of Dermatology, 153, 1105-1113.
Kurokawa, I., Danby, F.W., Ju, Q., Wang, X., Xiang, L.F., Xia, L., Chen, WC., Nagy, I., Picardo, M., Suh, D.H., Ganceviciene, R., Schagen, S., Tsatsou, F. and Zouboulis C.C. (2009) New Developments in Our Understanding of Acne Pathogenesis and Treatment. Experimental Dermatology, 18, 821-832.
Christos, C., Hristos, C. and Zouboulis, M.D. (2004) Acne and Sebaceous Gland Function. Clinics in Dermatology, 22, 360-366.
|||Cunliffe, W.J. (1989) Acne. Martin Dunitz, London.|
|||Downing, D.T., Stewart, M.E. and Strauss, J.S. (1989) Changes in Sebum Secretion and the Sebaceous Gland. Clinics in Geriatric Medicine, 5, 109-114.|
|||Smith, K.R. and Thiboutot, D.M. (2008) Sebaceous Gland Lipids: Friend or Foe? Journal of Lipid Research, 49, 271-281.|
|||Stewart, M.E. (1992) Sebaceous Glands Lipids. Seminars in Dermatology, 11, 100-105.|
Zouboulis, C.C., Jourdan, E. and Picardo, M. (2014) Acne Is an Inflammatory Disease and Alterations of Sebum Composition Initiate Acne Lesions. Journal of the European Academy of Dermatology and Venereology, 28, 527-532.
|||Fritsh, M., Orfanos, C.E. and Zouboulis, C.C. (2001) Sebocytes Are the Key Regulators of Androgen Homeostasis in Human Skin. Journal of Investigative Dermatology, 116, 793-800.|
Pappas, A. (2009) Epidermal Surface Lipids. Dermatoendocrinology, 1, 72-76.
Rosenfield, R.L., Deplewski, D., Kentsis, A. and Ciletti, N. (1998) Mechanisms of Androgen Induction of Sebocyte Differentiation. Dermatology, 196, 43-46.
Degitz, K., Placzek, M., Borelli, C. and Plewig, G. (2007) Pathophysiology of Acne. Journal der Deutschen Dermatologischen Gesellschaft, 5, 316-323.
Deplewski, D. and Rosenfield, R.L. (1999) Growth Hormone and Insulin-Like Growth Factors Have Different Effects on Sebaceous Cell Growth and Differentiation. Endocrinology, 140, 4089-4094.
Cappel, M., Mauger, D. and Thiboutot, D. (2005) Correlation between Serum Levels of Insulin-Like Growth Factor 1, Dehydroepiandrosterone Sulfate, and Dihydrotestosterone and Acne Lesion Count in Adult Women. Archives of Dermatology, 141, 333-338.
Tasli, L., Turgut, S., Kacar, N., Ayada, C., Coban, M., Akcilar, R. and Ergin, S. (2013) Insulin-Like Growth Factor-I Gene Polymorphism in Acne Vulgaris. Journal of the European Academy of Dermatology and Venereology, 27, 254-257.
Im, M., Kim, S.Y., Sohn, K.C., Choi, D.K., Lee, Y., Seo, Y.J., Kim, C.D., Hwang, Y.L., Zouboulis, C.C. and Lee, J.H. (2012) Epigallocatechin-3-Gallate Suppresses IGF-I-Induced Lipogenesis and Cytokine Expression in SZ95 Sebocytes. Journal of Investigative Dermatology, 132, 2700-2708.
Van Aller, G.S., Carson, J.D., Tang, W., Peng, H., Zhao, L., Copeland, R.A., Tummino, P.J. and Luo, L. (2011) Epigallocatechin Gallate (EGCG), a Major Component of Green Tea, Is a Dual Phosphoinositide-3-kinase/mTOR Inhibitor. Biochemical and Biophysical Research Communications, 406, 194-199.
|||Adams, J.C. and Morehart, A.L. (1982) Decline and Death of Pinus spp. in Delaware Caused by Bursaphelenchus xylophilus. Journal of Nematology, 14, 382-385.|
|||Zhu, J., Gonda, Y., Yu, L., Li, F., Yan, Q. and Sun, Y. (2012) Regeneration of a Coastal Pine (Pinus thunbergii Parl.) Forest 11 Years after Thinning, Niigata, Japan. Public Library of Science One, 7, e47593.|
|||Taniguchi, T., Kanzaki, N., Tamai, S., Yamanaka, N. and Futai, K. (2007) Does Ectomycorrhizal Fungal Community Structure Vary along a Japanese Black Pine (Pinus thunbergii) to Black Locust (Robinia pseudoacacia) Gradient? New Phytologist, 173, 322-334.|
Won, J.N., Lee, S.Y., Song, D.S. and Poo, H. (2013) Antiviral Activity of the Plant Extracts from Thuja orientalis, Aster spathulifolius, and Pinus thunbergii against Influenza Virus A/PR/8/34. Journal of Microbiology and Biotechnology, 23, 125-130.
Hong, S.S., Jeong, W., Kim, J.K., Kwon, J.G., Lee, J.Y., Ahn, E.K., Oh, J., Seo, D.W. and Oh, J.S. (2014) Neolignan Inhibitors of Antigen-Induced Degranulation in RBL-2H3 Cells from the Needles of Pinus thunbergii. Fitoterapia, 99, 347-351.
Deng, Y., Liu, Z. and Geng, Y. (2016) Anti-Allergic Effect Artemisia Extract in Rats. Experimental and Therapeutic Medicine, 12, 1130-1134.
Mueller, M.S., Runyambo, N., Wagner, I., Borrmann, S., Dietz, K. and Heide, L. (2004) Randomized Controlled Trial of a Traditional Preparation of Artemisia annua L. (Annual Wormwood) in the Treatment of Malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 98, 318-321.
Klayman, D.L. (1985) Qinghaosu (Artemisinin): An Antimalarial Drug from China. Science, 228, 1049-1055.
Zhao, Y.G., Wang, Y., Guo, Z., Gu, A.D., Dan, H.C., Baldwin, A.S., Hao, W. and Wan, Y.Y. (2012) Dihydroartemisinin Ameliorates Inflammatory Disease by Its Reciprocal Effects on Th and Regulatory T Cell Function via Modulating the Mammalian Target of Rapamycin Pathway. The Journal of Immunology, 189, 4417-4425.
Radulović, N.S., Randjelović, P.J., Stojanović, N.M., Blagojević, P.D., Stojanović-Radić, Z.Z., Ilić, I.R. and Djordjević, V.B. (2013) Toxic Essential Oils. Part II: Chemical, Toxicological, Pharmacological and Microbiological Profiles of Artemisia annua L. Volatiles. Food and Chemical Toxicology, 58, 37-49.
Wu, X., Zhang, W., Shi, X., An, P., Sun, W. and Wang, Z. (2010) Therapeutic Effect of Artemisinin on Lupus Nephritis Mice and Its Mechanisms. Acta Biochimica et Biophysica Sinica (Shanghai), 42, 916-923.
|||Bamunuarachchi, G.S., Ratnasooriya, W.D., Premakumara, S. and Udagama, P.V. (2013) Antimalarial Properties of Artemisia vulgaris L. Ethanolic Leaf Extract in a Plasmodium berghei Murine Malaria Model. Journal of Vector Borne Diseases, 50, 278-284.|
Yoo, K.M., Lee, K.W., Park, J.B., Lee, H.J. and Hwang, I.K. (2004) Variation in Major Antioxidants and Total Antioxidant Activity of Yuzu (Citrus junos Sieb ex Tanaka) during Maturation and between Cultivars. Journal of Agricultural and Food Chemistry, 2, 5907-5913.
Sawamura, M., Wu, Y., Fujiwara, C. and Urushibata, M. (2005) Inhibitory Effect of Yuzu Essential Oil on the Formation of N-Nitrosodimethylamine in Vegetables. Journal of Agricultural and Food Chemistry, 53, 4281-4287.
|||Kim, S.H., Hur, H.J., Yang, H.J., Kim, H.J., Kim, M.J., Park, J.H., Sung, M.J., Kim, M.S., Kwon, D.Y. and Hwang, J.T. (2013) Citrus junos Tanaka Peel Extract Exerts Antidiabetic Effects via AMPK and PPAR-γ both In Vitro and In Vivo in Mice Fed a High-Fat Diet. Evidence-Based Complementary and Alternative Medicine, 2013, Article ID: 921012.|
Shin, E.J., Park, J.H., Sung, M.J., Chung, M.Y. and Hwang, J.T. (2016) Citrus junos Tanaka Peel Ameliorates Hepatic Lipid Accumulation in HepG2 Cells and in Mice Fed a High-Cholesterol Diet. BMC Complementary and Alternative Medicine, 16, 499.
|||Konno, N. (2009) Mental Caring for Pre-Symptomatic Depression by Aroma—Effects of Lemon and Yuzu Essential Oil. Aroma Research, 39, 260-263.|
Green, L.C., Wagner, D.A., Glogowski, J., Skipper, P.L., Wishnok, J.S. and Tannenbaum, S.R. (1982) Analysis of Nitrate, Nitrite, and [15N] Nitrate in Biological Fluids. Analytical Biochemistry, 126, 131-138.
Frosch, P.J. and Kligman, A.M. (1979) The Soap Chamber Test. A New Method for Assessing the Irritancy of Soaps. Journal of the American Academy of Dermatology, 1, 35-41.
|||Graham, G.M., Farrar, M.D., Cruse-Sawyer, J.E., Holland, K.T. and Ingham, E. (2004) Proinflammatory Cytokine Production by Human Keratinocytes Stimulated with Propionibacterium acnes and GroEL. British Journal of Dermatology, 150, 421-428.|
Nagy, I., Pivarcsi, A., Kis, K., Koreck, A., Bodai, L., McDowell, A., Seltmann, H., Patrick, S., Zouboulis, C.C. and Kemény, L. (2006) Propionibacterium acnes and Lipopolysaccharide Induce the Expression of Antimicrobial Peptides and Proinflammatory Cytokines/Chemokines in Human Sebocytes. Microbes and Infection, 8, 2195-2205.
|||Guin, J.D., Huber, D.S. and Gielerak, P.L. (1979) Antibiotic Sensitivity of Comedonal Propionibacterium acnes. Acta Dermato-Venereologica, 59, 552-554.|
Jappe, U. (2003) Pathological Mechanisms of Acne with Special Emphasis on Propionibacterium acnes and Related Therapy. Acta Dermato-Venereologica, 83, 241-248.
Pretsch, A., Nagl, M., Schwendinger, K., Kreiseder, B., Wiederstein, M., Pretsch, D., Genov, M., Hollaus, R., Zinssmeister, D., Debbab, A., Hundsberger, H., Eger, A., Proksch, P. and Wiesner, C. (2014) Antimicrobial and Anti-Inflammatory Activities of Endophytic Fungi Talaromyces wortmannii Extracts against Acne-Inducing Bacteria. Public Library of Science One, 9, e97929.
Trompezinski, S., Weber, S., Cadars, B., Larue, F., Ardiet, N., Chavagnac-Bonneville, M., Sayag, M. and Jourdan, E. (2016) Assessment of a New Biological Complex Efficacy on Dysseborrhea, Inflammation, and Propionibacterium acnes Proliferation. Clinical, Cosmetic and Investigational Dermatology, 9, 233-239.
Yoon, J.Y., Kwon, H.H., Min, S.U., Thiboutot, D.M. and Suh, D.H. (2013) Epigallocatechin-3-Gallate Improves Acne in Humans by Modulating Intracellular Molecular Targets and Inhibiting P. acnes. Journal of Investigative Dermatology, 133, 429-440.
Copyright © 2020 by authors and Scientific Research Publishing Inc.
This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.